On March 1, 2022, the Center for Drug Evaluation of the State Drug Administration announced that ATAP-M8 was approved by the Center for Drug Evaluation of the State Drug Administration (hereinafter referred to as CDE) to officially enter human clinical trials and carry out Clinical trials in advanced solid tumors.